GoodRx (GDRX) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue was $196 million, up slightly year-over-year, with net income of $1.1 million and a net income margin of 0.6%.

• Adjusted EBITDA reached $66.3 million (33.8% margin), a 2% increase from the prior year.

• The company expanded partnerships with major pharmaceutical manufacturers and retail pharmacies, and launched new affordability and brand campaigns.

• Acquired VCRX for $30 million and ScriptDrop for $13.5 million to enhance prescription transactions and delivery capabilities.

• Over 6 million prescription-related consumers used the platform in Q3, but Monthly Active Consumers declined to 5.4 million from 6.5 million a year ago.

Financial highlights

• Q3 2025 total revenue was $196 million, with manufacturer solutions revenue up 54% year-over-year to $43.4 million.

• Prescription transaction revenue declined 9% year-over-year to $127.3 million.

• Subscription revenue decreased 3% to $20.7 million, with plans dropping to 671,000.

• Ended Q3 with $273.5 million in cash and $80 million unused credit facility capacity.

• Repurchased 13.4 million shares for $61.6 million; $81.4 million remains under the $450 million repurchase program.

Outlook and guidance

• Full-year 2025 revenue guidance remains unchanged, expected to exceed $792 million.

• Q4 revenue expected to decline sequentially due to accelerated manufacturer solutions deals in Q3.

• Full-year adjusted EBITDA projected to grow 2%-6% over 2024, with margins in line with year-to-date trends.

• Manufacturer solutions projected to grow approximately 35% in 2025.

• Near-term pressure on prescription transactions revenue and Monthly Active Consumers is expected due to retail pharmacy closures, PBM network changes, and integrated savings program volume reductions, with an estimated $35–$40 million revenue impact in 2025.